US Stock MarketDetailed Quotes

UNCY Unicycive Therapeutics

Watchlist
  • 0.5300
  • +0.0022+0.42%
Close Nov 22 16:00 ET
  • 0.5421
  • +0.0121+2.28%
Post 20:02 ET
55.01MMarket Cap-1152P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    AdrianHHA
    AdrianHHA
    Nov 14 05:32
    $Unicycive Therapeutics (UNCY.US)$
    H.C. Wainwright raised the firm’s  on Unicycive Therapeutics () to $4 from $2.50 and keeps a Buy rating on the shares following the Q3 report.
    Published first on  – the ultimate source for real-time, market-moving breaking financ
    Jaguar8
    Jaguar8
    Nov 13 06:16
    NEWS ER
    $Unicycive Therapeutics (UNCY.US)$
    Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
    Positive
    FDA acceptance of OLC New Drug Application with PDUFA date set for June 28, 2025
    Strong patient preference for OLC: 79% preferred it over prior therapy
    Successful completion of UNI-494 Phase 1 trial with positive safety profile
    Patent granted for UNI-494 valid until 2040
    Cash runway extended into 2026 with $32.3M cash position
    Reduced net loss to $4.1M from $4.4...
    Jaguar8
    Jaguar8
    Nov 11 06:03
    NEWS
    $Unicycive Therapeutics (UNCY.US)$
    Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
    Unicycive Therapeutics announced FDA acceptance of its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis. The FDA set a PDUFA target date of June 28, 2025. OLC aim...
    Jaguar8
    Jaguar8
    Oct 28 06:19
    NEWS
    $Unicycive Therapeutics (UNCY.US)$
    Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
    Unicycive Therapeutics (UNCY) presented multiple studies at ASN Kidney Week 2024, highlighting progress on oxylanthanum carbonate (OLC) and UNI-494. The late-breaking presentation showed OLC enabled serum phosphate control in >90% of chronic kidney disease pati...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data